REGENXBIO (NASDAQ:RGNX) Rating Reiterated by William Blair

REGENXBIO (NASDAQ:RGNXGet Free Report)‘s stock had its “neutral” rating restated by equities researchers at William Blair in a note issued to investors on Tuesday, RTT News reports. They currently have a $21.00 price target on the biotechnology company’s stock, up from their previous price target of $20.00. William Blair’s price objective suggests a potential upside of 9.72% from the company’s previous close.

Several other research firms have also recently issued reports on RGNX. StockNews.com assumed coverage on REGENXBIO in a report on Thursday, October 5th. They issued a “hold” rating on the stock. Stifel Nicolaus initiated coverage on REGENXBIO in a research report on Wednesday, November 1st. They set a “buy” rating and a $35.00 price objective on the stock. Wedbush reaffirmed a “neutral” rating and set a $20.00 price objective on shares of REGENXBIO in a research report on Thursday, October 5th. Morgan Stanley lowered their target price on shares of REGENXBIO from $43.00 to $42.00 and set an “overweight” rating for the company in a research note on Tuesday, August 29th. Finally, Royal Bank of Canada reiterated a “sector perform” rating and set a $20.00 target price on shares of REGENXBIO in a research note on Wednesday, October 4th. Five equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $31.13.

Get Our Latest Stock Report on RGNX

REGENXBIO Trading Up 0.5 %

RGNX stock opened at $19.14 on Tuesday. REGENXBIO has a 12-month low of $12.82 and a 12-month high of $25.54. The stock has a market cap of $841.97 million, a price-to-earnings ratio of -3.20 and a beta of 1.12. The business’s 50-day moving average is $16.52 and its 200 day moving average is $18.08.

REGENXBIO (NASDAQ:RGNXGet Free Report) last posted its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($1.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.44) by $0.03. REGENXBIO had a negative return on equity of 59.54% and a negative net margin of 262.18%. The company had revenue of $28.90 million for the quarter, compared to analysts’ expectations of $26.14 million. During the same period in the previous year, the firm posted ($1.75) EPS. REGENXBIO’s revenue was up 9.1% compared to the same quarter last year. As a group, equities analysts forecast that REGENXBIO will post -5.07 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of RGNX. Captrust Financial Advisors grew its stake in REGENXBIO by 742.1% in the 1st quarter. Captrust Financial Advisors now owns 960 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 846 shares during the period. Royal Bank of Canada raised its stake in shares of REGENXBIO by 189.8% in the 3rd quarter. Royal Bank of Canada now owns 1,397 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 915 shares in the last quarter. Northwestern Mutual Wealth Management Co. bought a new stake in shares of REGENXBIO during the 4th quarter valued at about $38,000. PNC Financial Services Group Inc. grew its position in shares of REGENXBIO by 103.6% during the 2nd quarter. PNC Financial Services Group Inc. now owns 1,963 shares of the biotechnology company’s stock valued at $39,000 after buying an additional 999 shares during the last quarter. Finally, Headlands Technologies LLC bought a new stake in shares of REGENXBIO during the 2nd quarter valued at about $44,000. 88.80% of the stock is currently owned by institutional investors and hedge funds.

About REGENXBIO

(Get Free Report)

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.

Featured Articles

Analyst Recommendations for REGENXBIO (NASDAQ:RGNX)

Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter.